Company
Headquarters: Miami Beach, FL, United States
CEO: Dr. Nardo Zaias
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Suvanza Pharma, LLC operates as an early-stage biotechnology corporation and engages in the development of the skin drug delivery system, RapiDerm for dermatologic diseases. Suvanza Pharma, LLC was formerly known as Hamilton PNG and changed its name to Suvanza Pharma, LLC in March 2010. The company was founded in 2004 and is based in Miami Beach, Florida.
Suvanza has the following listings and related stock indices.
Stock: OTC: SUVZ wb_incandescent